Acifein

Quick links to important sections

Acifein

Selected form

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acifein

Property Description
Active Ingredients Acetaminophen, Acetylsalicylic Acid, Caffeine
Form Tablet or Capsule (Oral solid)
Pharmacological Class Combination Analgesic
General Purpose Pain Relief and Fever Reduction
Origin Synthetic

Acifein is an over-the-counter (OTC) medication classified as a Fixed-Dose Combination (FDC) medicinal product. It is known primarily for its ability to relieve general discomfort and reduce fever, a characteristic that is clinically recognized in pharmacological literature for this specific triple-component formulation. This medicine, typically available as a tablet or capsule, is often the preferred choice when users seek a rapid, multi-action approach for common temporary ailments.


Components and Purpose

The core identity of Acifein is defined by its three synthetic active components: Acetaminophen (a non-opioid pain reliever), Acetylsalicylic Acid (Aspirin), and Caffeine. While Acetaminophen and Aspirin are the agents that address discomfort and fever, Caffeine is included as an adjuvant, meaning it boosts the effectiveness and speed of the two main drugs.

This specific inclusion of caffeine is a key differentiating factor of Acifein and similar fixed-dose combinations, as caffeine is included to increase the speed of pain relief compared to taking the pain relievers alone. The combination is generally purposed to offer accelerated and multi-pronged relief for general aches and fever.

The Benefit of a Multi-Action Formula

The three-way approach provides a strong therapeutic strategy through synergy. The formula is designed to ensure that the medicine targets pain and fever through distinct physiological pathways simultaneously—one component acts on the central nervous system, and another provides anti-inflammatory action.

The rationale for these fixed-dose combinations is based on their potential to exhibit enhanced efficacy for acute pain management. In simple terms, the drug's design allows it to tackle the perception of pain and the underlying factors like inflammation more comprehensively than a single-action medicine.

What side effects are possible with Acifein?

Possible side effects and safety information

The official safety information for this medicine details potential adverse reactions and safety restrictions based on government regulatory documentation. Adverse reactions are formally categorized by the frequency of occurrence and the specific system or organ affected.

Serious Safety Risks and Contraindications

The medicine's safety profile includes specific warnings regarding serious risks associated with its components (acetaminophen and ibuprofen/NSAID). These include:

  • Hepatotoxicity: Risk of serious, potentially fatal, liver damage, primarily linked to the acetaminophen component, especially with high cumulative doses.
  • Cardiovascular Events: Increased risk of serious cardiovascular thrombotic events, such as heart attack and stroke, which may increase with the duration of use.
  • Gastrointestinal Events: Risk of serious gastrointestinal adverse events, including bleeding, ulceration, and perforation of the stomach or intestines.
  • Severe Skin Reactions: Potential for rare but severe skin reactions, such as Stevens-Johnson Syndrome.

Contraindications restrict the use of this medicine in specific circumstances, including individuals with a known hypersensitivity to any component (including NSAIDs or aspirin), patients with severe heart failure, active bleeding, or severe hepatic or renal impairment.

Commonly Documented Side Effects

Adverse reactions that are frequently documented in regulatory sources typically involve the following system-organ classes:

  • Gastrointestinal Disorders: Including dyspepsia (indigestion), nausea, vomiting, and abdominal pain.
  • Nervous System Disorders: Such as headache and dizziness.
  • Skin and Subcutaneous Tissue Disorders: Including rash.

Safety Limitations and Restrictions

Official safety documents mandate restrictions on concurrent use with other substances. Patients are restricted from taking this medicine simultaneously with other products containing acetaminophen or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) to avoid exceeding maximum daily limits and increasing the risk of serious side effects.

Overdose and Emergency Response

The official regulatory profile for Acifein overdose outlines specific manifestations stemming from its three active components, mandating urgent professional intervention. Initial signs may include non-specific gastrointestinal symptoms such as nausea, vomiting, sweating, and abdominal pain, often followed by signs unique to the combination, such as ringing in the ears (tinnitus), confusion, or a rapid heartbeat.

Documented Risks and Outcomes

The most critical documented outcome is the risk of severe hepatic injury (liver damage or necrosis) associated with the acetaminophen component, which can be delayed and potentially fatal. Overdose involving the Acetylsalicylic Acid component may also lead to severe metabolic acidosis and neurological effects like seizures. Susceptibility to severe toxic effects may be increased in patients with pre-existing liver impairment.

Emergency Actions Mandated by Regulators

Regulatory bodies explicitly state that immediate medical help must be sought right away, even if symptoms are not immediately apparent. Due to the time-sensitive nature of treatment, contact a Poison Control Center or emergency services immediately following a suspected overdose. The specific antidote, N-Acetylcysteine (NAC), is required to prevent or lessen the severe liver toxicity. Management procedures include prompt laboratory assessment of drug concentrations and continuous observation in a hospital setting.

Therapeutic Uses of Acifein

What Acifein Treats: Main Uses and Benefits

The primary role of Acifein is to provide symptomatic relief across several key domains of acute discomfort, addressing symptoms related to physical discomfort and systemic imbalance.

This combination is indicated for the temporary relief of minor aches and pains due to headache, muscular aches, colds, arthritis, toothache, and menstrual cramps.

Management of Acute Symptom Clusters

This medication is commonly used to help with symptoms related to primary headache disorders, including both episodic tension-type headaches and the acute phases of migraine attacks. It is applied across domains where additional symptomatic support is needed for pronounced symptoms that create noticeable functional strain. The core therapeutic benefit helps address symptom clusters that may become intense, contributing to improved comfort during periods of heightened symptoms.

It also provides broad analgesic and antipyretic support for mild to moderate pain and elevated body temperature. It is relevant across contexts involving heightened systemic burden, such as generalized aches linked to acute viral illnesses. This supportive relief helps ease the overall symptom burden and assists with maintaining functional stability when symptoms are more noticeable.

Quick Fact: Symptomatic Relief Domains
Symptom Axes: Symptoms related to physical discomfort and heightened physiological activity.
Conditions: Conditions involving episodic or fluctuating manifestations, such as primary headache.
Patient Benefit: Supports general well-being during symptomatic phases and assists with maintaining functional stability.

Regulatory References

  1. NIH DailyMed overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Acifein? — Official Regulatory Information

The eligibility to use Acifein is defined by regulatory authorities based on patient age, concurrent health status, and pre-existing conditions.

Eligibility Scope Restrictions and Prohibitions
Populations Allowed Generally, adults who do not have documented contraindications. Older adults may use it but require caution due to increased risk of bleeding.
Populations Contraindicated Absolute non-eligibility applies to patients with known hypersensitivity (allergy) to any component, active gastrointestinal bleeding or peptic ulcers, or a congenital bleeding disorder.

Age-Related Eligibility Rules

  • Pediatric and Adolescent Use: Use is generally not recommended or contraindicated in children and teenagers, particularly those under 16 years of age, unless explicitly advised by a physician. This is critical for patients recovering from or having a viral illness (like flu or chickenpox), due to the associated risk of Reye's Syndrome.
  • Pregnancy and Lactation: The medicine is contraindicated during the third trimester of pregnancy. Use during the first and second trimesters and while breastfeeding is subject to strict professional consultation.

Condition-Specific Eligibility Rules

Use is restricted or not recommended for patients with moderate to severe hepatic (liver) impairment or renal (kidney) impairment. Patients must also refrain from using Acifein with any other product containing acetaminophen or if there is chronic heavy alcohol consumption, as these combinations increase the risk of severe liver damage.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Acifein, a fixed-dose combination of Acetaminophen, Acetylsalicylic Acid (Aspirin), and Caffeine, presents several documented interaction patterns primarily based on the components' established effects as defined in official regulatory labeling.


Documented Pharmacological Interactions

Interaction Type Interacting Substances/Classes Interaction Outcome (Regulatory Description)
Contraindicated Combinations Other Acetaminophen products, Monoamine Oxidase Inhibitors (MAOIs) Prohibited co-administration due to risk of severe liver damage or acute hypertensive episodes.
Pharmacodynamic Risk Anticoagulants (e.g., Warfarin), SSRIs Increased risk of hemorrhage or gastrointestinal bleeding due to additive antiplatelet effects.
Pharmacokinetic Risk CYP1A2 Inhibitors (e.g., Fluconazole), Probenecid May decrease clearance of caffeine or interfere with the elimination of Aspirin and Acetaminophen, potentially increasing plasma levels.

Restrictions and Timing-Based Rules

Co-administration with alcohol (ethanol) is restricted due to the combined risk of severe liver damage from Acetaminophen and stomach bleeding from Aspirin. Use must also be limited with other caffeine-containing products to avoid excessive stimulation. The regulatory profile notes that co-administration of Ibuprofen may interfere with the antiplatelet benefit of low-dose Aspirin, sometimes necessitating a timing separation rule to maintain the desired effect. The risk of toxicity from interactions is officially considered more significant in populations such as the elderly and those with hepatic impairment.

Mechanism of Action

Receptor-Mediated Signaling Modulation

Acifein acts within domains involving receptor-mediated signaling, primarily engaging mechanisms that modulate overactive or dysregulated processes within the target system. This engagement initiates or suppresses specific signaling sequences, modifying early molecular steps, and results in altered pathway activity within targeted molecular targets.


Targeted Pathway Adjustment in Neural Systems

The agent is relevant in systems where specific transmitters or mediators dominate, influencing biological systems associated with heightened physiological responses. Acifein modifies key pathways by altering activity that may escalate under certain conditions. This results in changes in physiological responses following the modification of excessive mediator activity.


Influence on Feedback Regulation

Acifein also engages mechanisms that influence feedback regulation within biological cascades, regulating processes driven by distinct signaling patterns. This is relevant in systems where multiple layers of pathway activation occur, influencing feedback regulation and reducing the intensity of overactive physiological responses by adjusting systemic physiological outcomes.

Dosage and Administration Information

Acifein is administered via the oral route as an oral solid, commonly supplied as a film-coated tablet or caplet. The medicine is used on an as-needed basis, following a highly standardized, non-prescriptive regimen for adults and children 12 years and over.

The standard single dose consists of two tablets/caplets, which delivers 500 mg of acetaminophen, 500 mg of aspirin, and 130 mg of caffeine. To maintain safe usage parameters, this single dose should not be repeated more frequently than every six hours. Furthermore, usage is limited to a maximum dose of eight tablets/caplets within a 24-hour period.

Proper administration requires that each single dose be swallowed with a full glass of water, a key procedural condition specified for the product. The administration protocol includes constraints on simultaneous drug use, prohibiting the concurrent use of any other product containing acetaminophen and requiring users to limit the intake of external caffeine sources.

Overall usage is strictly intended for short-term use only. Guidelines specify that the medicine should not be used for more than 10 days for pain relief or three days for fever; for acute migraine management, use is typically limited to 10 days per month. The use of this combination product in children under 12 years requires consultation with a healthcare professional.

Recent Clinical Evidence

Research evidence / Overview of Studies for Acifein

The research evidence for the Acifein combination analgesic, which contains acetaminophen, acetylsalicylic acid (aspirin), and caffeine, is mainly rooted in clinical trials designed to evaluate the combination's performance in research exploring short-term symptom changes in acute situations. The primary focus of this research has been on understanding how symptoms are measured over defined, short time intervals in specific adult populations.


Evidence for Use in Primary Headache Disorders

Research exploring how symptoms change over time in conditions characterized by fluctuating or episodic manifestations, such as primary headache disorders, has been a major focus for this combination. Studies conducted during periods of increased symptom activity include short-term Randomized Controlled Trials (RCTs). Researchers monitored outcomes related to physical discomfort, specifically examining metrics such as the time interval until a symptomatic change was reported and the proportion of participants monitored for a pain-free state or a specific level of pain intensity change.

Studies report how symptoms evolved in the observed populations, and findings describe patterns observed in the studies when the combination was evaluated in acute settings. Research highlights changes measured during the study period, particularly regarding the time to an initial symptomatic change when compared to inactive treatments.


Research on General Acute Pain and Fever

The combination was studied for broader outcomes related to systemic or functional imbalance, specifically for general acute pain and the outcomes linked to physiological strain or stress such as elevated body temperature. Research examined measures like overall pain intensity scores and antipyretic outcomes, which reflect changes in elevated body temperature, across conditions where symptoms may vary in intensity, such as muscular aches, cold-related pain, and dental pain.

Findings indicate patterns related to short-term changes in patient-reported outcomes describing perceived discomfort and temperature. Evidence contributes to the broader evidence landscape related to recognized pharmacological strategies for monitoring outcomes related to physical discomfort and outcomes related to systemic or functional imbalance.


Research Limitations and Follow-up Duration

Research has primarily focused on episodes where symptoms become more noticeable, meaning follow-up durations were limited. Consequently, data for outcomes related to the effects or safety patterns associated with the long-term, frequent, or daily use of the combination analgesic are not well characterized in the available RCT literature. Research reports how symptoms evolved in populations of generally healthy adults experiencing acute pain. This means that the results apply only to the populations studied, and data for certain groups, such as older adults, pregnant individuals, or those with significant comorbid conditions, remain insufficient.

Key Studies & References

  1. Review of the Efficacy of Fixed-Dose Combinations for Acute Pain Management (NIH Bookshelf)
  2. NIH DailyMed Monograph: Acetaminophen, Aspirin, and Caffeine Combination

Frequently Asked Questions (FAQ)

Common questions about Acifein (FAQ)

Q: How quickly should I expect Acifein to relieve pain?

Studies cited in regulatory documents indicate that the time until users report an initial change in symptoms is generally observed within 30 minutes of taking the medication. This observation is based on results from clinical research evaluating the combination's performance in acute pain scenarios.

Q: Are there specific foods or drinks officially recommended to avoid while taking Acifein?

Official documents restrict co-administration with alcohol due to combined safety risks. Additionally, official information advises limiting the intake of other caffeine-containing products. Regulatory information does not typically list restrictions on specific foods.

Q: Does Acifein commonly cause drowsiness?

Official product information does not list drowsiness as a frequently documented adverse reaction for this medication. While adverse reactions involving the nervous system are common, the regulatory documentation does not state that the drug often causes sleepiness.

Q: What are the common mild side effects reported for Acifein?

Frequently documented adverse reactions include gastrointestinal disturbances such as dyspepsia (indigestion), nausea, and vomiting. Nervous system effects like dizziness and headache are also commonly reported in official documentation.

Q: What are the potential risks of taking Acifein with alcohol described in official documents?

Official documentation states that co-administration with alcohol carries a combined risk. This risk includes severe liver damage (primarily due to the acetaminophen component) and an increased risk of gastrointestinal bleeding (linked to the aspirin component).

Q: Is Acifein known to interact with caffeine consumption?

The official product information indicates a limitation on the use of other caffeine-containing products. This restriction is necessary to avoid excessive central nervous system stimulation and to prevent potentially high plasma levels of the caffeine component in the medicine.

Q: Does Acifein interact with common cold or flu medications?

Regulatory documents specify a restriction on the concurrent use of any other product containing acetaminophen or other NSAIDs. This is to prevent the risk of exceeding established maximum daily limits and increasing serious side effect risk.

Q: Are there warnings about liver function associated with Acifein?

The safety profile includes specific warnings about hepatotoxicity. This is the risk of serious, potentially fatal, liver damage linked primarily to the acetaminophen component of the combination drug.

Q: Does the product label mention any risk for stomach irritation?

Official labeling mentions the risk of serious gastrointestinal adverse events, including bleeding, ulceration, and perforation. Common reactions also noted are dyspepsia (indigestion) and abdominal pain, which relate to stomach discomfort.

Q: What is the typical patient profile described in clinical trials for Acifein?

Clinical trials used to establish the performance and safety profile for Acifein primarily focused on populations of generally healthy adults. These studies investigated short-term episodes of acute pain, and the results apply only to the populations studied.

Q: How is Acifein different from regular over-the-counter pain medicine?

Acifein is described in official labeling as a fixed-dose combination of three active ingredients: acetaminophen, aspirin, and caffeine. This combination is described as working together to address symptoms in specific acute pain scenarios, distinguishing it from single-ingredient pain relievers.

Q: Why is Acifein available by prescription in some regions and over-the-counter in others?

Official governmental classifications of drug availability are determined individually by each country’s regulatory body. These decisions are typically based on factors such as established safety data, the drug's formulation, and the established maximum allowed daily dose limits in that specific market.

Q: Can I take Acifein on an empty stomach?

The official administration protocol requires the single dose to be swallowed with a full glass of water. While the labeling specifies this procedural condition, it does not provide explicit instruction regarding the condition of the stomach (full or empty).

Q: Is it normal to feel jittery when taking Acifein?

Due to the caffeine component included in the combination, nervous system adverse reactions such as tremor or restlessness are sometimes reported in official documentation. These are symptoms associated with central nervous system stimulation.

Q: Is Acifein considered an NSAID (Nonsteroidal Anti-inflammatory Drug)?

The combination product contains Acetylsalicylic Acid (Aspirin), which is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). The regulatory risk profile for Acifein includes warnings associated with both the NSAID component and the acetaminophen component.

Q: Does Acifein contain any components that regulatory bodies have warned are habit-forming?

Official regulatory classification documents, such as those governing controlled substances, do not list any components of Acifein as having a high potential for dependence or abuse. This medication is not classified as a controlled substance.

Q: Why do some users report a 'rebound' headache after discontinuing Acifein?

Official regulatory documents often include warnings regarding the potential development of medication-overuse headache. This condition is associated with the frequent or prolonged use of combination analgesics for headache symptoms.

Q: What is the difference between Acifein and a simple acetaminophen product?

Acifein differs from a simple acetaminophen product by including two additional ingredients. These are acetylsalicylic acid (aspirin), which is an NSAID, and caffeine, which is described in regulatory documents as an analgesic adjuvant.

Q: Is Acifein available as a generic drug formulation?

Regulatory records indicate that formulations containing the same active ingredients in the same dosage are generally available from various manufacturers. This is common after the original manufacturer's period of exclusivity has ended.

Q: What is the role of each active ingredient in Acifein?

Acetaminophen and aspirin both contribute to pain and fever relief as described in pharmacological properties. Caffeine is included and is characterized as an analgesic adjuvant, meaning it enhances the effects of the other ingredients.

Q: Why does Acifein sometimes carry a warning about potential heart issues?

Safety warnings regarding serious cardiovascular thrombotic events, such as heart attack and stroke, are associated with the Nonsteroidal Anti-inflammatory Drug (NSAID) component of the combination drug. This warning often appears in the most prominent section of the official prescribing information.

Q: What types of comparative studies have been conducted on Acifein and similar pain relievers?

Clinical trials cited in regulatory documents primarily compare the performance of the fixed-dose combination product against an inactive treatment (placebo). They also compare the combination against its individual active components to establish the overall benefit of the formulation.

Q: Is there a maximum number of days Acifein should be used as described on the label?

Official instructions define limitations stating that use should not exceed 10 days for pain relief and three days for fever. For acute migraine management, the use is restricted to no more than 10 days per month.

Q: Why is Acifein sometimes mentioned in discussions about headache medicine overuse?

Discussions of overuse are driven by the regulatory warnings on the product regarding the risk of developing medication-overuse headache (MOH). This risk is associated with using combination analgesics frequently or for prolonged periods, especially for headache symptoms.

How should Acifein be stored and disposed of?

Storage and Disposal of Acifein

Acifein tablets must be stored at controlled room temperature, specifically maintained between 20 C to 25 C (68 F to 77 F). The official labeling requires that the container cap be closed tightly after use and the product be kept away from excessive heat and humidity to maintain stability.

Handling and Protection

The most important safety requirement is to keep out of reach of children. Consumers are instructed to discard any tablets that exhibit a strong vinegar smell, as this is a sign of product degradation. Unused or expired medication must be disposed of according to local guidelines for pharmaceutical waste disposal, and consumers must get rid of any unused medication after the expiration date.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Acifein found in:

A-Z Index: